Last reviewed 2026-04-20 · How we verify

GnRH antagonists

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Neutropenia
• Nausea
• Insomnia
• Hot flashes/flushes
• Fatigue
• Pain - Joint
• Alopecia
• Arthralgia
• Diarrhoea
• Fatigue (asthenia, lethargy, malaise)
• Neutrophil count decreased
• Anaemia

Key clinical trials

• Menopausal Hormones and Sympathetic Activation (PHASE4)
• Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation. (PHASE4)
• Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (PHASE2)
• A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (PHASE2)
• A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (PHASE2)
• Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (PHASE2)
• PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer (PHASE2, PHASE3)
• PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• GnRH antagonists CI brief — competitive landscape report
• GnRH antagonists updates RSS · CI watch RSS
• Novartis Pharmaceuticals portfolio CI